Trial results of next-gen weight-loss drug retatrutide bring it one step closer to FDA approval
While drugs such as Wegovy target a single gut hormone, retatrutide is among a new class of GLP-1 drugs that aims at three hormone receptors
Keep muscle while losing weight, even on Ozempic
Ozempic and just getting older take off muscle. New therapies could retain it
Quitting weight loss can cause weight regain—two strategies could help prevent that
With millions of people now using GLP-1 drugs such as Wegovy and Zepbound, scientists are racing to find ways to help people retain their weight loss after they stop taking the medication
Ozempic’s greatest benefit might be its anti-inflammatory power
A growing body of research suggests that GLP-1 drugs do more than control appetite and blood sugar. They could also fight inflammation
GLP-1 drugs like Ozempic don’t work for everyone. Genetic variants offer new clues
The weight you lose and the nausea you experience from GLP-1 drugs may be linked to common gene variants, but they can’t fully explain why some people lose more weight than others
The weight-loss drug rivalry heats up as another GLP-1 pill gains FDA approval
This week the U.S. Food and Drug Administration approved a second GLP-1 pill for weight loss. The drug, called Foundayo, resulted in an average of 27 pounds lost in 72 weeks
Weight loss was just the beginning: How the GLP-1 story is evolving
“Imitation” drugs, unexpected benefits, serious pitfalls—here’s what comes next as GLP-1 medications continue to rise in popularity
Ozempic and other new diabetes drugs revolutionize kidney treatment
Three types of diabetes medication are improving the outlook for patients with kidney disease
People who took GLP-1 drugs had lower risk of all kinds of drug and alcohol addiction
A large epidemiological study of more than 600,000 veterans with diabetes suggests GLP-1 weight-loss medications may reduce drug- and alcohol-related overdoses and deaths
Head-to-head trial pitting Eli Lilly’s oral GLP-1 against oral semaglutide underscores efficacy of weight-loss pills
A new trial found that Eli Lilly’s GLP-1 pill resulted in greater reductions in blood sugar levels and weight than oral semaglutide did, but fewer people stayed on it
Compound weight-loss drugs are everywhere. The FDA is cracking down
The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications
The next wave of GLP-1 drugs are coming—and they’re stronger than Wegovy and Zepbound
The upcoming drugs CagriSema and retatrutide target multiple gut hormones and could cause twice as much weight loss than current treatments. But experts wonder how much is too much